Signs of Tumor Lysis Syndrome
Tumor lysis syndrome presents with both laboratory abnormalities and clinical manifestations, with laboratory TLS defined by two or more metabolic derangements (hyperuricemia, hyperkalemia, hyperphosphatemia, or hypocalcemia), while clinical TLS requires these lab abnormalities plus serious complications like renal insufficiency, cardiac arrhythmias, or seizures. 1
Laboratory Signs (Laboratory TLS)
Laboratory TLS is present when two or more of the following metabolic abnormalities occur within 3 days before or 7 days after initiating treatment:
- Hyperuricemia (uric acid >8 mg/dL or 25% increase from baseline)
- Hyperkalemia (potassium elevated above normal or 25% increase)
- Hyperphosphatemia (phosphate elevated above normal or 25% increase)
- Hypocalcemia (calcium below normal or 25% decrease)
- Elevated creatinine (indicating renal dysfunction) 1
The Cairo-Bishop classification system is the most widely accepted framework, addressing limitations of earlier systems by accounting for patients with pre-existing abnormalities and extending the timeframe beyond just 4 days post-treatment 1.
Clinical Signs (Clinical TLS)
Clinical TLS requires laboratory TLS plus one or more of these serious complications:
Cardiac Manifestations
- Arrhythmias (ventricular tachycardia, fibrillation)
- Cardiac arrest
- Sudden death
These result primarily from hyperkalemia, which is the most immediately life-threatening electrolyte abnormality 1.
Neurological Manifestations
- Seizures
- Muscle cramps and tetany (from hypocalcemia)
- Paresthesias
- Syncope 1
Renal Manifestations
- Acute kidney injury/renal failure
- Hematuria
- Oliguria or anuria
- Uremia (elevated BUN)
Renal dysfunction occurs through multiple mechanisms: uric acid crystal precipitation in tubules, calcium phosphate deposition, and xanthine crystallization 1.
Gastrointestinal and General Symptoms
- Nausea and vomiting
- Diarrhea
- Anorexia
- Lethargy
- Edema and fluid overload
- Congestive heart failure 1
Timing of Presentation
Critical timing consideration: While TLS can occur spontaneously before treatment, symptoms most commonly appear within 12 to 72 hours after initiating cytoreductive therapy 1. This narrow window demands vigilant monitoring during this high-risk period.
Clinical Grading
The severity of clinical TLS is graded (I-IV) based on the maximal grade of the most severe clinical complication present, not simply by the number of abnormalities 1. This emphasizes that even a single severe complication (like cardiac arrest from hyperkalemia) defines high-grade TLS requiring aggressive intervention.
Common Pitfalls
Do not wait for multiple symptoms to develop before acting. A single critical electrolyte abnormality like severe hyperkalemia (>6.0 mEq/L) warrants immediate intervention regardless of other parameters. The retrospective data from Henry Ford Hospital demonstrated that high uric acid levels (≥8 mg/dL) carried an 11.66-fold increased risk of TLS compared to low levels, emphasizing the importance of early laboratory detection 1.
Recognize that laboratory TLS precedes clinical TLS. In one study of high-grade NHL patients, 42% had laboratory TLS but only 6% developed clinically significant symptoms requiring specific therapy 1. However, when clinical TLS does develop, mortality is substantially higher—83% in one AML cohort versus 24% in those with laboratory TLS alone 1.